ANT-045 / Antikor Biopharma - LARVOL DELTA

ANT045: A novel format, antibody fragment drug-conjugate (FDC) product for challenging cMET-expressing solid tumors (AACR 2026) - "ANT-045 demonstrates superior tumor cure efficacy in cMET high, moderate and low CDX and PDX gastric cancer xenograft models and better tolerability compared to the leading competitor ADCs, notably telisotuzumab vedotin. In a non-GLP, non-human primate study, ANT-045 was well tolerated with a predicted half-life in humans of around 12-14 hours supporting a viable clinical dosing strategy with a wide therapeutic window. Insights into how FDCs behave in vivo through quantitative uptake studies and toxicological parameters will be shared and how these have informed our follow-up products."

Gastric Cancer • Oncology • Solid Tumor

ANT-045: Demonstrating the promise of better penetrating, safer Antibody Fragment Drug-Conjugates (EORTC-NCI-AACR 2024) - "Complete cures were seen at doses as low as 0.5mg/kg (4 doses, once/week) demonstrating superiority to Phase 2 developmental benchmark ADC ABBV399 (telisotuzumab vedotin). Conclusions ANT-045 represents the next generation of ADC with a superior solid tumour penetrating and safety profile. Clinical evaluation is planned for 2026."

Gastric Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urethral Cancer

Gastric cancerantibody fragment drug-conjugates (FDCs): Applying a successful concept to solid tumours (AACR 2023) - "ANT-043 has pM potencies in a range of HER2-expressing cell-lines, including trastuzumab-resistant models, excellent tumour ablation effects in breast, ovarian and gastric cancer xenograft models and superior tolerability compared to an ADC in rat toxicology studies at a dose of 1mg/kg/weekly. ANT-045 has excellent in vitro cell-kill potency (pM IC50s) and excellent stability and superior in vivo tumour cure efficacy, compared to a leading clinical stage benchmark ADC. This presentation will focus on Antikor’s FDC discovery platform (stable high-DAR scFv-display libraries, tailored linker-payloads and design features) that has the potential to generate first-in-class products for difficult to treat solid tumours for patient benefit and promising to succeed where ADCs have failed to make an impact."

Gastric Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Oncology • Ovarian Cancer • Solid Tumor • Urethral Cancer

Gastric cancer antibody fragment drug-conjugates (FDCs): Succeeding in solid tumors where ADCs fail (AACR 2022) - "ANT-043 has pM potencies in a range of HER2-expressing cell-lines, including trastuzumab-resistant models, excellent tumor ablation effects in breast, ovarian and gastric cancer xenograft models and superior tolerability compared to an ADC in rat toxicology studies at a dose of 1mg/kg/weekly. ANT-045 has excellent in vitro cell-kill potency (pM IC50s) and excellent stability and superior in vivo tumor cure efficacy, compared to a leading clinical stage benchmark ADC. This presentation will focus on Antikor’s FDC discovery platform (stable high-DAR scFv-display libraries, tailored linker-payloads and design features) that has the potential to generate first-in-class products for difficult to treat solid tumors for patient benefit and promising to succeed where ADCs have failed to deliver."

Gastric Cancer • Gastrointestinal Cancer • Oncology • Ovarian Cancer • Solid Tumor

[VIRTUAL] Antibody fragment drug-conjugates (FDCs)-application of ANT-043 and ANT-045 in solid tumors (AACR 2021) - "This presentation will focus on ANT-045’s remarkable development and show that this FDC demonstrates superior efficacy and tolerability compared to an ADC when equated on an equi-mass, equi-molar and equi-payload basis. ANT-045 could be used to switch ‘immunologically-cold’ tumour ‘hot’ to benefit from checkpoint inhibitor therapy and data will be presented to support this concept."

Gastric Cancer • Gastrointestinal Cancer • Oncology • Ovarian Cancer • Solid Tumor